Vitamin D pp 357-373 | Cite as

Clinical Utility of 1,25-Dihydroxyvitamin D3 and Its Analogs for the Treatment of Psoriasis and Other Skin Diseases

  • J. Reichrath
  • Michael F. Holick
Chapter
Part of the Nutrition and Health book series (NH)

Abstract

Vitamin D is photochemically sythesized by ultraviolet (UV)B action in the skin (1, 2). It is now known that the skin itself is a target tissue for the secosteroid hormone 1 α,25-dihydroxyvitamin D3 [1,25(OH)2D3, calcitriol], the biologically active vitamin D metabolite (3,4). 1,25(OH)2D3 exerts genomic and nongenomic effects. Nongenomic effects of 1,25(OH)2D3 and its analogs are related to effects on intracellular calcium (5,6). In keratinocytes and other cell types, calcitriol rapidly increases free cytosolic calcium levels (5,6). Genomic effects of 1,25(OH)2D3 are mediated via binding to a nuclear receptor protein that is present in target tissues and binds 1,25(OH)2D3 with high affinity (K D 10−9−10−10 M) and low capacity (7,8). The human vitamin D receptor (VDR) has been cloned (9), and sequence analysis has demonstrated that this protein belongs to the superfamily of trans-acting transcriptional regulatory factors, which includes the steroid and thyroid hormone receptors and the retinoic acid receptors (9). Interaction of 1,25(OH)2D3 with VDR results in the phosphorylation of the receptor complex, which in turn activates the transcription of calcitriol-sensitive target genes, especially genes involved in cellular differentiation and proliferation. Recently, it was shown that VDRs require auxiliary factors for sufficient DNA binding (10). These auxiliary proteins were identified as the retinoid X receptors (RXR-α, -β,- γ), which were shown to heterodimerize with VDR, thus increasing the transcriptional function and DNA binding to the respective vitamin D response elements (VDRE) in the promotor region of target genes (10,11). In the skin, both VDR (Fig. 1) and RXR-α are expressed in keratinocytes, fibroblasts, Langerhans cells, sebaceous gland cells, endothelial cells, and most cell types related to the skin immune system (12,13). In vitro studies revealed that 1,25(OH)2D3 is extremely effective in inducing terminal differentiation and inhibiting the proliferation of cultured human keratinocytes in a dose-dependent manner (14–16). Additionally, 1,25(OH)2D3 acts on many cell types involved in immunologic reactions, including lymphocytes, macrophages, and Langerhans cells (17,18). Data on the effects of 1,25(OH)2D3 on the melanin pigmentation system are still conflicting, but most studies do not support the possibility that 1,25(OH)2D3 regulates melanogenesis in human skin (19).

Keywords

Psoriatic Skin Psoriatic Lesion Lesional Psoriatic Skin Nail Psoriasis Scalp Psoriasis 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. 1.
    Holick MF, MacLaughlin JA, Clark MB, Holick SA, Potts JT, Anderson RR, Blank IH, Parrish JA, Elias P: Photosynthesis of previtamin D3 in human skin and the physiological consequences. Science 1980; 210: 203–205.PubMedCrossRefGoogle Scholar
  2. 2.
    Holick MF, MacLaughlin JA, Anderson RR, Parrish J.: Photochemistry and photobiology of vitamin D. In: Photomedicine. Regan JD, Parrish JA eds. New York: Plenum Press, 1982; 195–218.CrossRefGoogle Scholar
  3. 3.
    Holick MF, Smith E, Pincus S: Skin as the site of vitamin D synthesis and target tissue for 1,25dihydroxyvitamin D3. Arch Dermatol 1987; 123: 1677–1682.PubMedCrossRefGoogle Scholar
  4. 4.
    Holick MF: Photobiology, physiology and clinical applications for Vitamin D. In: Physiology, Biochemistry and Molecular Biology of the Skin, 2nd ed. Goldsmith LA, ed. New York: Oxford University Press, 1991; 928–956.Google Scholar
  5. 5.
    Bittiner B, Bleehen SS, Mac Neil S: la-25-(OH)2Vitamin D3 increases intracellular calcium in human keratinocytes. Br J Dermatol 1991; 124: 12, 230–12, 235.Google Scholar
  6. 6.
    MacLaughlin JA, Cantley LC, Holick ME: 1,25(OH)2D3 increases calcium and phosphatidylinositol metabolism in differentiating cultured human keratinocytes. J Nutr Biochem 1990; 1: 81–87.PubMedCrossRefGoogle Scholar
  7. 7.
    Haussler MR: Vitamin D receptors: nature and function. Annu Rev Nutr 1986; 6: 527–562.PubMedCrossRefGoogle Scholar
  8. 8.
    Haussler MR, Mangelsdorf DJ, Komm BS, Terpening CM, Yamaoka K, Allegretto EA, Baker AR, Shine J, McDonnell DP, Hughes M, Weigel NL, O’Malley BW: Molecular biology of the vitamin D hormone. Recent Prog Horm Res 1988; 44: 263–305.PubMedGoogle Scholar
  9. 9.
    Baker AR, Mc Donnell DP, Hughes M, Crisp TM, Mangelsdorf DJ, Haussler MR, Pike JW, Shine J, O’Malley BW: Cloning and expression of full-length cDNA encoding human vitamin D receptor. Proc Natl Acad Sci USA 1988; 85: 3294–3298.PubMedCrossRefGoogle Scholar
  10. 10.
    Yu VC, Deisert C, Andersen B, Holloway JM, Devary OV, Näär AM, Kim SY, Boutin JM, Glass CK, Rosenfeld MG: RXR(3: a coregulator that enhances binding of retinoic acid, thyroid hormone and vitamin D receptors to their cognate response elements. Cell 1991; 67: 1251–1266.PubMedCrossRefGoogle Scholar
  11. 11.
    Leid M, Kastner P, Lyons R, Nakshatri H, Saunders M, Zacharewski T, Chen J, Staub A, Gamier J, Mader S, Chambon P: Purification, cloning, and RXR identity of the HeLa cell factor with which RAR or TR heterodimerizes to bind target sequences efficiently. Cell 1992; 68: 377–395.PubMedCrossRefGoogle Scholar
  12. 12.
    Milde P, Hauser U, Simon R, Mall G, Ernst V, Haussler MR, Frosch P, Rauterberg EW: Expression of 1,25-dihydroxyvitamin D3 receptors in normal and psoriatic skin. J Invest Dermatol 1991; 97: 230–239.PubMedCrossRefGoogle Scholar
  13. 13.
    Reichrath J, Münssinger T, Kerber A, Rochette-Egly C, Chambon P, Bahmer FA, Baum HP: In situ detection of retinoid-X receptor expression in normal and psoriatic human skin. Br J Dermatol 1995; 133: 168–175.PubMedCrossRefGoogle Scholar
  14. 14.
    Smith EL, Walworth NC, Holick MF: Effect of la-25-dihydroxyvitamin D3 on the morphologic and biochemical differentiation of cultured human epidermal keratinocytes grown under serum-free conditions. J Invest Dermatol 1986; 86: 709–714.PubMedCrossRefGoogle Scholar
  15. 15.
    Hosomi J, Hosoi J, Abe E, Suda T, Kuroki T: Regulation of terminal differentiation of cultured mouse epidermal cells by 1-alpha 25-dihydroxy-vitamin D3. Endocrinology 1983; 113: 1950–1957.PubMedCrossRefGoogle Scholar
  16. 16.
    Gniadecki R, Serup J: Stimulation of epidermal proliferation in mice with 1 alpha, 25-dihydroxyvitamin D3 and receptor-active 20-EPI analogues of 1 alpha, 25-dihydroxyvitamin D3. Biochem Pharmacol 1995; 49: 621–624.PubMedCrossRefGoogle Scholar
  17. 17.
    Rigby WFC: The immunobiology of vitamin D. Immunol Today 1988; 9: 54–58.PubMedCrossRefGoogle Scholar
  18. 18.
    Texereau M, Viac J: Vitamin D, immune system and skin. Eur J Dermatol 1992; 2: 258–264.Google Scholar
  19. 19.
    Ranson M, Posen S, Mason RS: Human melanocytes as a target tissue for hormones: in vitro studies with la,25-dihydroxyvitamin D3, alpha-melanocyte stimulating hormone, and beta-estradiol. J Invest Dermatol 1988; 91: 593–598.PubMedCrossRefGoogle Scholar
  20. 20.
    Christophers E, Henseler T: Psoriasis of early and late onset: characterization of two types of psoriasis vulgaris. J Am Acad Dermatol 1985; 13: 450–456.PubMedCrossRefGoogle Scholar
  21. 21.
    Christophers E, Henseler T: Patient subgroups and the inflammatory pattern in psoriasis. Acta Derm Venereol (Stockh) 1989; 69: 88–92.Google Scholar
  22. 22.
    Elder JT, Henseler T, Christophers E, Voorhees JJ, Nair RP: Of genes and antigens: the inheritance of psoriasis. J Invest Dermatol 1994; 103: 150S - 153SPubMedCrossRefGoogle Scholar
  23. 23.
    Valdimarsson H, Baker BS, Jonsdittir I, Fry L: Psoriasis: a disease of abnormal keratinocyte proliferation induced by T lymphocytes. Immunol Today 1986; 7: 256–259.CrossRefGoogle Scholar
  24. 24.
    Lee RE, Gaspari AA, Lotze MT, Chang AE, Rosenberg SA: Interleukin 2 and psoriasis. Arch Dermatol 1988; 124: 1811–1815.PubMedCrossRefGoogle Scholar
  25. 25.
    Barker JN, Jones ML, Mitra RS, Crockett Torab E, Fantone JC, Kunkel SL, Warren JS, Dixit VM, Nickoloff BJ: Modulation of keratinocyte derived interleukin-8 which is chemotactic for neutrophils and T lymphocytes. Am J Pathol 1991; 139: 869–876.PubMedGoogle Scholar
  26. 26.
    Gottlieb AB: Immunologic mechanisms in psoriasis. J Invest Dermatol 1990; 95: 18S - 29S.CrossRefGoogle Scholar
  27. 27.
    Schlaak JF, Buslau M, Jochum W, Hermann E, Girndt M, Gallati H, Meyer zum Büschenfelde KH, Fleischer B: T cells involved in psoriasis vulgaris belong to the Thl subset. J Invest Dermatol 1994; 102: 145–149.PubMedCrossRefGoogle Scholar
  28. 28.
    van Reijsen FC, Druijnzeel-Koomen CAFM, Kalthoff FS, Maggi E, Romagnani S, Westland JKT, Mudde GC: Skin-derived aeroallergen-specific T-cell clones of Th2 phenotype in patients with atopic dermatitis. J Allergy Clin Immunol 1992; 90: 184–192.PubMedCrossRefGoogle Scholar
  29. 29.
    Leung DY, Walsh P, Giorno R, Norris DA: A potential role for superantigens in the pathogenesis of psoriasis. J Invest Dermatol 1993; 100: 225–228.PubMedCrossRefGoogle Scholar
  30. 30.
    Chowaniec O, Jablonska S, Beutner EH, Proniewska M, Jarzabek Chorzelska M, Rzesa G: Earliest clinical and histological changes in psoriasis. Dermatologica 1981; 163: 42–51.PubMedCrossRefGoogle Scholar
  31. 31.
    MacLaughlin JA, Gange W, Taylor D, Smith E, Holick MF: Cultured psoriatic fibroblasts from involved and uninvolved sites have partial but not absolute resistance to the proliferation-inhibition activity of 1,25-dihydroxyvitamin D3. Proc Natl Acad Sci USA 1985; 82: 5409–5412.PubMedCrossRefGoogle Scholar
  32. 32.
    Morimoto S, Kumahara Y: A patient with psoriasis cured by la-hydroxyvitamin D3. Med J Osaka Univ 1985; 35: 3–4, 51–54.Google Scholar
  33. 33.
    Morimoto S, Yochikawa K, Kozuka T, Kitano Y, Imawaka S, Fukuo K, Koh E, Kumahara Y: An open study of vitamin D3 treatment in psoriasis vulgaris. Br J Dermatol 1986; 115: 421–429.PubMedCrossRefGoogle Scholar
  34. 34.
    Holick MF, Chen ML, Kong XF, Sanan DK: Clinical uses for calciotropic hormones 1,25-dihydroxyvitamin D3 and parathyroid hormone related peptide in dermatology: a new perspective. J Invest Dermatol (Symp Proc) 1996; 1: 1–9.Google Scholar
  35. 35.
    Perez A, Chen TC, Turner A, Raab R, Bhawan J, Poche P, Holick MF: Efficacy and safety of topical calcitriol (1,25-dihydroxyvitamin D3) for the treatment of psoriasis. Br J Dermatol 1996; 134: 238–246.PubMedCrossRefGoogle Scholar
  36. 36.
    Kragballe K, Beck HI, Sogaard H: Improvement of psoriasis by topical vitamin D3 analogue (MC 903) in a double-blind study. Br J Dermatol 1988; 119: 223–230.PubMedCrossRefGoogle Scholar
  37. 37.
    van de Kerkhof PCM, van Bokhoven M, Zultak M, Czarnetzki BM: A double-blind study of topical 1a-25-dihydroxyvitamin D3 in psoriasis. Br J Dermatol 1989, 120: 661–664.PubMedCrossRefGoogle Scholar
  38. 38.
    Perez A, Raab R, Chen TC, Turner A, Holick MF: Safety and efficacy of oral calcitriol (1,25dihydroxyvitamin D3) for the treatment of psoriasis. Br J Dermatol 1996; 134: 1070–1078.PubMedCrossRefGoogle Scholar
  39. 39.
    Kragballe K, Gjertsen BT, de Hoop D, Karlsmark T, van de Kerhof PCM, Larko O, Nieboer C, RoedPetersen J, Strand A, Tikjob B: Double-blind right/left comparison of calcipotriol and betametasone valerate in treatment of psoriasis vulgaris. Lancet 1991; 337: 193–196.PubMedCrossRefGoogle Scholar
  40. 40.
    Serup J: Calcipotriol irritation: mechanism, diagnosis and clinical implication. Acta Derm Venereol (Stockh) 1994; 186: 42S (abstract).Google Scholar
  41. 41.
    Green C, Ganpule M, Harris D, Kavanagh G, Kennedy C, Mallett, R, Rustin M, Downes N: Comparative effects of calcipotriol (MC 903) solution and placebo (vehicle of MC 903) in the treatment of psoriasis of the scalp. Br J Dermatol 1994; 130: 483–487.PubMedCrossRefGoogle Scholar
  42. 42.
    Petrow W: Treatment of a nail psoriasis with calcipotriol. Akt Dermatol 1995; 21: 396–400.Google Scholar
  43. 43.
    Saggese G, Federico G, Battini R: Topical application of 1,25 dihydroxyvitamin D3 (calcitriol) is an effective and reliable therapy to cure skin lesions in psoriatic children. Eur J Pediatr 1993; 152: 389–392.PubMedCrossRefGoogle Scholar
  44. 44.
    Perez A, Chen TC, Turner A, Holick MF: Pilot study of topical calcitriol (1,25-dihydroxyvitamin D3) for treating psoriasis in children. Arch Dermatol 1995; 131: 961–962.PubMedCrossRefGoogle Scholar
  45. 45.
    Grossman RM, Thivolet J, Claudy A, Souteyrand P, Guilhou JJ, Thomas P, Amblard P, Belaich S, de Belilovsky C, de la Brassinne M, et al. A novel therapeutic approach to psoriasis with combination calcipotriol ointment and very low-dose cyclosporine: a result of a multicenter placebo-controlled study. J Am Acad Dermatol 1994; 31: 68–74.PubMedCrossRefGoogle Scholar
  46. 46.
    Kerscher M, Volkenandt M, Plewig G, Lehmann P: Combination phototherapy of psoriasis with calcipotriol and narrow band UVB. Lancet 1993; 342: 923.PubMedCrossRefGoogle Scholar
  47. 47.
    Cambazard, van de Kerkhof PCM, Hutchinson PE, and the Calcipotriol Study Group. In: Proceedings of the 3rd International Calcipotriol Symposium, Munich, March 23, 1996.Google Scholar
  48. 48.
    Ortonne JP: Calcipotriol in combination with betametasone diproprionate. Nouv Dermatol 1994; 13: 736–751.Google Scholar
  49. 49.
    Kragballe K: Combination of topical calcipotriol (MC 903) and UVB radiation for psoriasis vulgaris. Dermatologica 1990; 181: 211–214.PubMedCrossRefGoogle Scholar
  50. 50.
    Lucker GP, van de Kerkhof PC, van Dijk MR, Steijlen PM: Effect of topical calcipotriol on congenital ichthyosis. Br J Dermatol 1994; 131: 546–550.PubMedCrossRefGoogle Scholar
  51. 51.
    Humbert P, Dupond JL, Agache P, Laurent R, Rochefort A, Drobacheff C, de Wazieres B, Aubin F: Treatment of scleroderma with oral 1,25-dihydroxyvitamin D3: evaluation of skin involvement using non-invasive techniques. Results of an open prospective trial. Acta Derm Venereol (Stockh) 1993; 73: 449–451.Google Scholar
  52. 52.
    Koeffler HP, Hirji K, Itri L: 1,25-Dihydroxyvitamin D3: in vivo and in vitro effects on human preleukemic and leukemic cells. Cancer Treat Rep 1985; 69: 1399–1407.PubMedGoogle Scholar
  53. 53.
    Colston KW, Chander SK, Mackay AG, Coombes RC: Effects of synthetic vitamin D analogues on breast cancer cell proliferation in vivo and in vitro. Biochem Pharmacol 1992; 44: 693–702.PubMedCrossRefGoogle Scholar
  54. 54.
    Franceschi RT, Linson CJ, Peter CT, Romano PR: Regulation of cellular adhesion and fibronectin synthesis by la,25-dihydroxyvitamin D3. J Biol Chem 1987; 262: 4165–4171.PubMedGoogle Scholar
  55. 55.
    Eisman JA, Barkla DH, Tutton PJM: Suppression of in vivo growth of human cancer solid tumor xenografts by la,25-dihydroxyvitamin D3. Cancer Res 1987; 47: 21–25.PubMedGoogle Scholar
  56. 56.
    Reichrath J, Müller SM, Kerber A, Baum HP, Bahmer FA: Biological effects of topical calcipotriol (MC 903) treatment in psoriatic skin. J Am Acad Dermatol 1997; 36: 19–28.PubMedCrossRefGoogle Scholar
  57. 57.
    Chen ML, Perez A, Sanan DK, Heinrich G, Chen TC, Holick MF: Induction of vitamin D receptor mRNA expression in psoriatic plaques correlates with clinical response to 1,25-dihydroxyvitamin D3. J Invest Dermatol 1996; 106: 637–641.PubMedCrossRefGoogle Scholar
  58. 58.
    Missero C, Calautti E, Eckner R, Chin J, Tsai LH, Livingston DM, Dotto GP: Involvement of the cell-cycle inhibitor Cipl/WAF1 and the E1A-associated p300 protein in terminal differentiation. Proc Natl Acad Sci USA 1995; 92: 5451–5455.PubMedCrossRefGoogle Scholar
  59. 59.
    Binderup L, Latini S, Binderup E, Bretting C, Calverley M, Hansen K: 20-Epi-vitamin D3 analogues: a novel class of potent regulators of cell growth and immune response. Biochem Pharmacol 1991; 42: 1569–1575.PubMedCrossRefGoogle Scholar
  60. Neef G, Kirsch G, Schwarz K, Wiesinger H. Menrad A, Fähnrich M, Thieroff-Eckerdt R, Steinmeyer A: 20-Methyl vitamin D analogues. In: Vitamin D. A Pluripotent Steroid Hormone: Structural Studies, Molecular Endocrinology and Clinical Applications. Norman AW, Bouillon R, Thomasset M, eds. Berlin: Walter de Gruyter, 1994; 97–98.Google Scholar
  61. 61.
    Schönecker B, Reichenbächer M, Gliesing S, Prousa R, Wittmann S, Breiter S, Thieroff-Eckerdt R, Wiesinger H, Haberey M, Scheddin D, Mayer H: 213-Substituted calcitriols and other A-ring substituted analogues-synthesis and biological results. In: Vitamin D. A Pluripotent Steroid Hormone: Structural Studies, Molecular Endocrinology and Clinical Applications. Norman AW, Bouillon R, Thomasset M, eds. Berlin: Thomasset M, eds. 1994; 99, 100.Google Scholar
  62. Schuster I, Herzig G, Vorisek G: Steroidal hormones as modulators of vitamin D metabolism in human keratinocytes. In: Vitamin D. A Pluripotent Steroid Hormone: Structural Studies, Molecular Endocrinology and Clinical Applications. Norman AW, Bouillon R, Thomasset M eds. Berlin: Walter de Gruyter, 1994;184–185.Google Scholar
  63. 63.
    Zhao J, Marcelis S, Tan BK, Verstuaf A, Boillon R: Potentialisation of vitamin D (analogues) by cytochrome P-450 enzyme inhibitors is analog-and cell-type specific. In: Vitamin D. A Pluripotent Steroid Hormone: Structural Studies, Molecular Endocrinology and Clinical Applications. Norman, AW, Bouillon R, Thomasset M, eds. Berlin: Thomasset M, eds. 1994; 186, 187.Google Scholar
  64. 64.
    Carlberg C, Bendik I, Wyss A, Meier E, Sturzenbecker LJ, Grippo JF, Hunziker W: Two nuclear signalling pathways for vitamin D. Nature 1993; 361: 657–660.PubMedCrossRefGoogle Scholar
  65. 65.
    Schräder M, Müller KM, Becker-Andre M, Carlberg C: Response element selectivity for heterodimerization of vitmain D receptors with retinoic acid and retinoid X receptors. J Mol Endocrinol 1994; 12: 327–339.PubMedCrossRefGoogle Scholar
  66. 66.
    Smith EL, Pincus SH, Donovan L, Holick MF: A novel approach for the evaluation and treatment of psoriasis. J Am Acad Dermatol 1988; 19: 516–528.PubMedCrossRefGoogle Scholar

Copyright information

© Springer Science+Business Media New York 1999

Authors and Affiliations

  • J. Reichrath
  • Michael F. Holick

There are no affiliations available

Personalised recommendations